Dr. Uy discusses preliminary results from a phase I trial of flotetuzumab, a CD123 x CD3 bispecific DART protein, in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes, as well as the challenges of finding new targets in AML.
